Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as α1-adrenergic receptor antagonists

Toxicology and Applied Pharmacology

Volumn 160, Issue 3, 1999, Pages 289-296

  Iversen, Patrick L ^a   Cornish, Kurtis G ^a   Iversen, Laurie J ^a   Mata, John E ^a   Bylund, David B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Hypotension; Oligodeoxynucleotide; Phosphorothioate; 1 adrenergic receptor

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PRAZOSIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SCREENING; HYPOTENSION; MACACA; MALE; NONHUMAN; RHESUS MONKEY; SYMPATHETIC TONE;

ANIMALIA; MACACA; MACACA MULATTA; PRIMATES;

EID: 0033229815     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8771     Document Type: Article

References (51)

1. Abraham W. C., Logan B., Thompson V. L., Williams J. M., Tate W. P. Sequence-independent effects of phosphorothiolated oligonucleotides on synaptic transmission and excitability in the hippocampus in vivo. Neuropharmacology. 36:1997;345-352.
2. Agrawal S., Temsamani J., Galbraith W., Tang J. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28:1995;7-16.
3. Agrawal S., Zhang R. Pharmacokinetics of oligonucleotides. Ciba Found. Symp. 209:1997;60-75.
4. Benimetskaya L., Tonkinson J. L., Koziolkiewicz M., Karwowski B., Guga P., Zeltser R., Stec W., Stein C. A. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res. 23:1995;4239-4245.
5. Bennett M. R., Lindner V., DeBlois D., Reidy M. A., Schwartz S. M. Effect of phosphorothioated oligonucleotides on neointima formation in the rat carotid artery. Dissecting the mechanism of action. Arterioscler. Thromb. Vasc. Biol. 17:1997;2326-2332.
6. Bishop M. R., Iversen P. L., Bayever E., Sharp J. G., Greiner T. C., Copple B. L., Ruddon R., Zon G., Spinolo J., Arneson M., Armitage J. O., Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies [see comments]. J. Clin. Oncol. 14:1996;1320-1326.
7. Broaddus W. C., Chen Z. J., Prabhu S. S., Loudon W. G., Gillies G. T., Phillips L. L., Fillmore H. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery. 41:1997;908-915.
8. Burgess T. L., Fisher E. F., Ross S. L., Bready J. V., Qian Y. X., Bayewitch L. A., Cohen A. M., Herrera C. J., Hu S. S., Kramer T. B. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA. 92:1995;4051-4055.
9. Bylund D. B., Blaxall H. S., Iversen L. J., Caron M. G., Lefkowitz R. J., Lomasney J. W. Pharmacological characteristics of alpha 2-adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol. Pharmacol. 42:1992;1-5.
10. Bylund D. B., Snyder S. H. Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol. Pharmacol. 12:1976;568-580.
11. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
12. Citro G., D'Agnano I., Leonetti C., Perini R., Bucci B., Zon G., Calabretta B., Zupi G. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res. 58:1998;283-289.
13. Cornish K. G., Gilmore J. P. Sino-aortic denervation in the monkey. J. Physiol. (Lond.). 360:1985;423-432.
14. Cornish K. G., Iversen P. L., Smith L., Arneson M., Bayever E. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesis monkey. Pharmacol. Commun. 3:1993;239-247.
15. Crooke S. T. Basic principles of antisense therapeutics. Antisense Research and Application. 1998;Springer-Verlag, Berlin. p. 1-50.
16. Cucco C., Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 56:1996;4332-4337.
17. Dasso L. L., Taylor C. W. Heparin and other polyanions uncouple alpha 1-adrenoceptors from G-proteins. Biochem. J. 280:1991;791-795.
18. Del Bufalo D., Cucco C., Leonetti C., Citro G., D'Agnano I., Benassi M., Geiser T., Zon G., Calabretta B., Zupi G. Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br. J. Cancer. 74:1996;387-393.
19. DeLong R. K., Nolting A., Fisher M., Chen Q., Wickstrom E., Kligshteyn M., Demirdji S., Caruthers M., Juliano R. L. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev. 7:1997;71-77.
20. Desjardins J. P., Iversen P. L. Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J. Pharmacol. Exp. Ther. 275:1995;1608-1613.
21. Fujimoto K., Takahashi M. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Biochem. Biophys. Res. Commun. 241:1997;775-781.
22. Galbraith W. M., Hobson W. C., Giclas P. C., Schechter P. J., Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4:1994;201-206.
23. Garcia-Sainz J. A. Characterization of the alpha-1 adrenoceptors of rat white fat cells. Eur. J. Pharmacol. 87:1983;159-161.
24. Grindel J. M., Musick T. J., Jiang Z., Roskey A., Agrawal S. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev. 8:1998;43-52.
25. Hangai M., Tanihara H., Honda Y., Kaneda Y. In vivo delivery of phosphorothioate oligonucleotides into murine retina. Arch. Ophthalmol. 116:1998;342-348.
26. Henry S. P., Bolte H., Auletta C., Kornbrust D. J. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology. 120:1997;145-155.
27. Iversen P. Antisense Technologies - Cambridge Healthtech Institute Conference. IDrugs. 1:1998;538-540.
28. Iversen P. L., Mata J., Tracewell W. G., Zon G. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 4:1994;43-52.
29. Jaillon P. Clinical pharmacokinetics of prazosin. Clin. Pharmacokinet. 5:1980;365-376.
30. Jansen B., Wadl H., Inoue S. A., Trulzsch B., Selzer E., Duchene M., Eichler H. G., Wolff K., Pehamberger H. Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res. Dev. 5:1995;271-277.
31. Jones S. B., Halenda S. P., Bylund D. B. Alpha 2-adrenergic receptor stimulation of phospholipase A2 and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms. Mol. Pharmacol. 39:1991;239-245.
32. 125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone. J. Pharmacol. Exp. Ther. 241:1987;875-881.
33. Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., Klinman D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
34. Kutryk J. B. DNA therapy does not prevent re-narrowing of a stented coronary artery. The European Society of Cardiology. 1998.
35. Leonetti C., D'Agnano I., Lozupone F., Valentini A., Geiser T., Zon G., Calabretta B., Citro G. C., Zupi G. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice [see comments]. J. Natl. Cancer Inst. 88:1996;419-429.
36. Levin A. A., Monteith D. K., Leeds J. M., Nicklin P. L., Geary R. S., Butler M., Templin M. V., Henry S. P. Toxicity of oligonucleotide therapeutic agents. Crooke S. T. Antisense Research and Application. 1998;169-215 Springer-Verlag, Berlin.
37. Moriya K., Matsukura M., Kurokawa K., Koike K. In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochem. Biophys. Res. Commun. 218:1996;217-223.
38. Nakazono K., Ito Y., Wu C. H., Wu G. Y. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology. 23:1996;1297-1303.
39. Sawai K., Mahato R. I., Oka Y., Takakura Y., Hashida M. Disposition of oligonucleotides in isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J. Pharmacol. Exp. Ther. 279:1996;284-290.
40. Schapel G. J., Betts W. H. The effect of a single oral dose of prazosin on venous reflex response, blood pressure and pulse rate in normal volunteers. Br. J. Clin. Pharmacol. 12:1981;873-881.
41. Shi Y., Fard A., Galeo A., Hutchinson H. G., Vermani P., Dodge G. R., Hall D. J., Shaheen F., Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 90:1994;944-951.
42. Srinivasan S. K., Tewary H. K., Iversen P. L. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5:1995;131-139.
43. Stein C. A., Cheng Y. C. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical. Science. 261:1993;1004-1012.
44. 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry. Anal. Biochem. 188:1990;11-16.
45. Steward A., Christian R. A., Hamilton K. O., Nicklin P. L. Co-administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): A role for the scavenger receptor in its in vivo disposition. Biochem. Pharmacol. 56:1998;509-516.
46. Teasdale R. M., Matson S. J., Fisher E., Krieg A. M. Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. Antisense Res. Dev. 4:1994;295-297.
47. Temsamani J., Roskey A., Chaix C., Agrawal S. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide. Antisense Nucleic Acid Drug Dev. 7:1997;159-165.
48. Wallace T. L., Bazemore S. A., Kornbrust D. J., Cossum P. A. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278:1996;1306-1312.
49. Wang W., Chen H. J., Schwartz A., Cannon P. J., Stein C. A., Rabbani L. E. Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98:1996;443-450.
50. Williams S. A., Gillan E. R., Knoppel E., Buzby J. S., Suen Y., Cairo M. S. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: Implications for the treatment of Burkitt's lymphoma. Ann. Oncol. 8:1997;25-30.
51. Zhang R., Lu Z., Zhang X., Zhao H., Diasio R. B., Liu T., Jiang Z., Agrawal S. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin. Chem. 41:1995;836-843.